Autoimmune Diseases: When the Immune System Attacks the Body

How the Body Normally Prevents Self-Attack

The immune system possesses elaborate mechanisms to distinguish self from non-self, collectively called immunological tolerance. Central tolerance operates during immune cell development in the thymus (for T cells) and bone marrow (for B cells). Developing T cells that strongly recognize self-antigens presented by thymic epithelial cells are eliminated through a process called negative selection, in which more than 95 percent of developing T cells die before ever reaching the bloodstream. Similarly, B cells in the bone marrow that produce antibodies targeting self-molecules are either killed, rendered permanently unresponsive (anergized), or forced to edit their antibody genes to change their specificity.

Central tolerance is highly effective but not perfect. Some self-reactive lymphocytes inevitably escape into the periphery, either because the self-antigens they recognize are not expressed in the thymus or bone marrow, or because the affinity of their receptors falls just below the threshold for negative selection. Peripheral tolerance mechanisms serve as a backup. Regulatory T cells (Tregs), identified by the transcription factor Foxp3, actively suppress self-reactive T cells in the tissues. Peripheral anergy renders self-reactive cells unresponsive when they encounter their target antigen without the co-stimulatory signals normally provided during infection. Activation-induced cell death eliminates self-reactive cells that become repeatedly stimulated.

Autoimmune disease develops when one or more of these tolerance mechanisms fails. The triggers are usually multifactorial, involving a combination of genetic susceptibility, environmental exposures, and stochastic immune events that together breach the multiple layers of self-protection.

Genetic and Environmental Risk Factors

Genetics play a substantial role in autoimmune susceptibility. The strongest genetic associations are with genes in the major histocompatibility complex (MHC), particularly the HLA (human leukocyte antigen) genes that encode the cell-surface proteins responsible for presenting antigens to T cells. The HLA-B27 allele increases the risk of ankylosing spondylitis by more than 100-fold. HLA-DR4 is strongly associated with rheumatoid arthritis. HLA-DQ2 and HLA-DQ8 together account for nearly all genetic risk for celiac disease. These associations make sense mechanistically: different HLA alleles present different peptide repertoires to T cells, and certain alleles may present self-peptides in ways that promote autoimmune T cell activation.

Non-HLA genes also contribute. Polymorphisms in CTLA-4, a T cell checkpoint receptor, increase the risk of type 1 diabetes and autoimmune thyroid disease. Variants in PTPN22, a phosphatase that regulates T cell receptor signaling, are associated with rheumatoid arthritis, lupus, and type 1 diabetes. Mutations in the AIRE gene, which controls the expression of tissue-specific antigens in the thymus, cause autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a syndrome in which multiple endocrine organs are attacked because T cells reactive to their antigens were never eliminated during thymic development.

Environmental triggers are equally important. Infections are the most studied environmental risk factor, and several mechanisms have been proposed. Molecular mimicry occurs when a microbial antigen structurally resembles a self-antigen closely enough that immune responses against the microbe cross-react with host tissues. Rheumatic fever, in which antibodies against streptococcal M protein cross-react with cardiac myosin, is the classic example. Bystander activation occurs when an infection creates a pro-inflammatory environment that nonspecifically activates self-reactive lymphocytes that would normally remain quiescent. Epitope spreading occurs when tissue damage caused by an initial immune response releases new self-antigens that become targets of secondary autoimmune responses, creating a cascade of widening autoimmunity.

Other environmental factors include smoking (a strong risk factor for rheumatoid arthritis and multiple sclerosis), vitamin D deficiency (associated with MS, type 1 diabetes, and lupus), the gut microbiome (disruptions in commensal bacteria populations are linked to inflammatory bowel disease, rheumatoid arthritis, and type 1 diabetes), and exposure to certain chemicals and drugs. The rising incidence of autoimmune diseases in industrialized nations over the past 50 years, a period too short for significant genetic change, strongly suggests that environmental factors are becoming more important.

Major Types of Autoimmune Diseases

Autoimmune diseases are broadly categorized as organ-specific or systemic, depending on whether the immune attack is directed at a single organ or at antigens found throughout the body.

Type 1 diabetes is an organ-specific autoimmune disease in which CD8+ cytotoxic T cells and CD4+ helper T cells destroy the insulin-producing beta cells of the pancreatic islets of Langerhans. The process typically begins years before symptoms appear, with autoantibodies against beta cell antigens (insulin, glutamic acid decarboxylase, islet antigen 2, and zinc transporter 8) detectable in the blood long before enough beta cells have been destroyed to cause hyperglycemia. By the time of clinical diagnosis, 80 to 90 percent of beta cell mass has been lost. Type 1 diabetes affects approximately 9 million people worldwide and requires lifelong insulin replacement therapy.

Multiple sclerosis (MS) is an autoimmune disease targeting the myelin sheath that insulates nerve fibers in the central nervous system. Autoreactive T cells, assisted by B cells and macrophages, infiltrate the brain and spinal cord and attack myelin-producing oligodendrocytes, creating plaques of demyelination that disrupt nerve signal transmission. Symptoms depend on where the plaques form and can include vision loss, numbness, weakness, balance problems, and cognitive impairment. MS affects approximately 2.8 million people globally, with a female-to-male ratio of about 3 to 1.

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily attacks the synovial membrane lining the joints. The immune response generates an inflammatory pannus, a mass of proliferating synovial cells, macrophages, and lymphocytes that invades cartilage and bone, causing progressive joint destruction. TNF-alpha, IL-6, and IL-1 are the dominant pro-inflammatory cytokines driving joint damage. RA affects roughly 1 percent of the global population and, if untreated, leads to significant disability within 10 years of diagnosis.

Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease, characterized by autoantibodies against nuclear antigens, including double-stranded DNA, histones, and ribonucleoproteins. These autoantibodies form immune complexes that deposit in the kidneys, skin, joints, blood vessels, and brain, activating complement and recruiting inflammatory cells. Lupus nephritis, the kidney manifestation, is the leading cause of morbidity and mortality in SLE, affecting approximately 50 percent of patients. SLE has a striking demographic skew, disproportionately affecting women of childbearing age, particularly those of African, Hispanic, and Asian descent.

Other notable autoimmune conditions include Hashimoto's thyroiditis (the most common autoimmune disease overall, causing hypothyroidism through destruction of thyroid tissue), Graves' disease (hyperthyroidism caused by stimulatory autoantibodies against the TSH receptor), inflammatory bowel disease (Crohn's disease and ulcerative colitis, in which immune responses against gut bacteria or mucosal antigens cause chronic intestinal inflammation), and celiac disease (an immune reaction to the gluten protein gliadin that damages the small intestinal lining).

How Autoimmune Diseases Are Treated

Traditional treatment of autoimmune diseases relied on broad immunosuppressive drugs, corticosteroids and cytotoxic agents like methotrexate, cyclophosphamide, and azathioprine, that suppressed the entire immune system rather than targeting the specific pathways driving autoimmunity. While effective at reducing inflammation and tissue damage, these drugs increase susceptibility to infections and cancers as side effects of their indiscriminate immune suppression.

The biologic revolution, beginning in the late 1990s, introduced targeted therapies that block specific cytokines, cell surface molecules, or signaling pathways. TNF-alpha inhibitors (adalimumab, infliximab, etanercept) transformed the treatment of rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Anti-IL-6 receptor antibodies (tocilizumab) are used for RA and giant cell arteritis. Anti-CD20 antibodies (rituximab) deplete B cells and are effective in RA, lupus, and MS. Anti-IL-17 antibodies (secukinumab) target the Th17 pathway in psoriasis and ankylosing spondylitis. Each of these therapies blocks a specific immunological node while leaving the rest of the immune system relatively intact.

Small-molecule inhibitors have expanded the targeted therapy arsenal further. JAK inhibitors (tofacitinib, baricitinib, upadacitinib) block Janus kinase enzymes that transduce signals from multiple cytokine receptors simultaneously, offering broad anti-inflammatory effects in an oral pill. S1P receptor modulators (fingolimod, ozanimod) trap lymphocytes in lymph nodes, preventing them from migrating to sites of autoimmune tissue damage, and are used in MS and ulcerative colitis. CTLA-4 fusion proteins (abatacept) block T cell co-stimulation, reducing T cell activation in RA.

Emerging approaches aim for something more ambitious than suppression: actual restoration of tolerance. Regulatory T cell therapy involves expanding a patient's own Tregs in the laboratory and infusing them back to suppress autoimmune responses. Antigen-specific tolerization uses nanoparticles or modified peptides to retrain the immune system to ignore specific self-antigens without broadly suppressing immunity. CAR-T cell therapy, originally developed for cancer, is being adapted to deplete the specific B cell clones that produce pathogenic autoantibodies. Early clinical trials of these approaches have shown promising results, and they represent a potential shift from lifelong symptom management to actual disease reversal.